2-[(2-Hydroxyethyl)amino]-2-methyl-1,3-propanediol | 137196-77-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(2-Hydroxyethyl)amino]-2-methyl-1,3-propanediol
• 英文别名: 2-(2-hydroxyethylamino)-2-methylpropane-1,3-diol
• CAS: 137196-77-1
• 化学式: C₆H₁₅NO₃
• 分子量: 149.19
• InChiKey: HQEMPHNKLPJTPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Pyrrolopyrimidines as therapeutic agents
  申请人：——

  公开号：US20030153752A1

  公开（公告）日：2003-08-14

  Chemical compounds having structural formula I 1 and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant refections and imflammatory disorders.

  具有结构式I1的化合物及其生理上可接受的盐和代谢物是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症和高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• [EN] PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS<br/>[FR] PYRROLOPYRIMIDINES UTILISEES COMME INHIBITEURS DE TYROSINE KINASES
  申请人：BASF AG

  公开号：WO2001072751A1

  公开（公告）日：2001-10-04

  Chemical compounds having structural formula (I), and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, transplant rejections and ifplammatory disorders.

  具有结构式（I）的化合物及其生理上可接受的盐和代谢物是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的多种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以缓解血管生成或内皮细胞过度增殖是疾病状态的情况。这些化合物可用于治疗癌症和高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
  申请人：novosom AG

  公开号：EP1911443A1

  公开（公告）日：2008-04-16

  An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

  一种两性脂质体，由脂质混合物组成，所述混合物包括阳离子两性化合物、阴离子两性化合物和一种或多种中性两性化合物、所述阳离子和阴离子双亲化合物中至少有一种是可带电的，且阳离子和阴离子双亲化合物各自的量应选择为：在第一个较低的 pH 值下，带正电的阳离子双亲化合物按比例过量，在第二个较高的 pH 值下，带负电的阴离子双亲化合物按比例过量，且所述混合物的等电点介于所述第一和第二 pH 值之间；其特征在于，所述带正电荷的阳离子和带负电荷的阴离子两性化合物可在所述等电点相互形成脂盐。还公开了预测两性脂质体在给定 pH 值下的溶融性、配制两性脂质体和用货物分子装载两性脂质体的方法。
• US6713474B2
  申请人：——

  公开号：US6713474B2

  公开（公告）日：2004-03-30